BR112017027285A2 - ?cocristal, composição farmacêutica e método para o tratamento de uma doença? - Google Patents

?cocristal, composição farmacêutica e método para o tratamento de uma doença?

Info

Publication number
BR112017027285A2
BR112017027285A2 BR112017027285A BR112017027285A BR112017027285A2 BR 112017027285 A2 BR112017027285 A2 BR 112017027285A2 BR 112017027285 A BR112017027285 A BR 112017027285A BR 112017027285 A BR112017027285 A BR 112017027285A BR 112017027285 A2 BR112017027285 A2 BR 112017027285A2
Authority
BR
Brazil
Prior art keywords
cocrystal
disease
treating
pharmaceutical composition
present
Prior art date
Application number
BR112017027285A
Other languages
English (en)
Inventor
Liu Xiaozhong
Original Assignee
Syn Nat Products Entpr Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn Nat Products Entpr Llc filed Critical Syn Nat Products Entpr Llc
Publication of BR112017027285A2 publication Critical patent/BR112017027285A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

a presente invenção se refere às séries de cocristais de carboplatina com as amidas cíclicas como coformadores e à sua utilização farmacêutica. os cocristais da presente invenção podem ser utilizados no tratamento ou prevenção de cânceres.
BR112017027285A 2015-06-19 2016-06-20 ?cocristal, composição farmacêutica e método para o tratamento de uma doença? BR112017027285A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562182142P 2015-06-19 2015-06-19
PCT/US2016/038340 WO2016205785A1 (en) 2015-06-19 2016-06-20 Pharmaceutical composition of carboplatin based co-crystals and use thereof

Publications (1)

Publication Number Publication Date
BR112017027285A2 true BR112017027285A2 (pt) 2018-09-11

Family

ID=57546414

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027285A BR112017027285A2 (pt) 2015-06-19 2016-06-20 ?cocristal, composição farmacêutica e método para o tratamento de uma doença?

Country Status (9)

Country Link
US (1) US10421770B2 (pt)
EP (1) EP3297636B1 (pt)
JP (1) JP6768716B2 (pt)
KR (1) KR20180018800A (pt)
CN (1) CN107847508B (pt)
AU (1) AU2016279099B2 (pt)
BR (1) BR112017027285A2 (pt)
CA (1) CA2988992A1 (pt)
WO (1) WO2016205785A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6851989B2 (ja) 2015-05-18 2021-03-31 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬用共結晶及びその用途
KR20180018800A (ko) 2015-06-19 2018-02-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 카보플라틴 계 공-결정의 약제학적 조성물 및 이의 용도
US10980768B2 (en) 2015-06-19 2021-04-20 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
CA2989001A1 (en) 2015-06-25 2016-12-29 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922689A (en) 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6297245B1 (en) 1998-08-04 2001-10-02 Unitech Pharmaceuticals Cisplatin and folic acid administered to treat breast cancer
KR100317473B1 (ko) 1999-05-11 2001-12-22 이계호 신규의 백금(ｉｖ)착제 및 그 제조방법
CN1121380C (zh) 2000-03-03 2003-09-17 北京兴大豪斯科技有限公司 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
DE60138739D1 (de) * 2001-11-30 2009-06-25 Jingzun Wang Supermolekulare carboplatinderivate, deren herstellung und pharmazeutische zusammensetzungen, die diese als wirkstoffe enthalten, sowie anwendungen der zusammensetzungen
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
BR0313593A (pt) 2002-08-19 2005-07-12 Pfizer Prod Inc Terapia de combinação para doenças hiperproliferativas
CA2514733A1 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004099224A1 (de) 2003-05-05 2004-11-18 Universität Regensburg Carboplatin-artige platin (ii)- komplexe
DE602004015811D1 (de) 2003-08-13 2008-09-25 Univ South Florida Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
CA2548281C (en) * 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
BRPI0606480A (pt) 2005-01-21 2008-03-11 Astex Therapeutics Ltd compostos farmacêuticos
CN100500219C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种含铂类化合物的抗实体肿瘤药物组合物
BRPI0708004A2 (pt) 2006-01-30 2011-05-17 Platco Technologies Proprietary Ltd preparação de complexos de platina (ii)
HUE026693T2 (hu) 2006-08-02 2016-07-28 Sunesis Pharmaceuticals Inc (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil) -1,8-naftiridin-3-karbonsav és cytarabin (Ara-C) kombinált alkalmazása leukémia kezelésére
MY148438A (en) * 2007-03-02 2013-04-30 Novartis Ag Solid forms of a raf kinase inhibitor
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
KR100957125B1 (ko) * 2008-01-14 2010-05-11 한국과학기술원 생체 고분자와 난용성 물질의 접합체 및 그의 제조방법
CN102149703B (zh) 2008-09-15 2014-09-10 卡斯娜莱拉伊诺制药私人有限公司 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症
CZ302618B6 (cs) 2009-09-10 2011-08-03 Univerzita Palackého Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
US20110287110A1 (en) 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP5179628B2 (ja) * 2011-07-15 2013-04-10 ユニーテック株式会社 ４価白金錯体及びそれを含む医薬組成物
US9220705B2 (en) * 2013-03-07 2015-12-29 James David Hoeschele Method of treating colorectal cancer
SG11201602962PA (en) * 2013-10-17 2016-05-30 Vertex Pharma Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
CN107167482B (zh) * 2014-08-13 2020-07-14 北京默加农生物技术发展有限公司 一种以双环铂为有效成分的药物的检测方法
CN104127402B (zh) 2014-08-15 2019-08-30 北京默加农生物技术发展有限公司 双环铂在制备抗病毒药物和抗菌药物中的应用
CN104693245A (zh) * 2015-03-13 2015-06-10 卓越同达医药科技开发（苏州）有限公司 超分子抗癌药物双环铂的制备方法
JP6925318B2 (ja) 2015-04-10 2021-08-25 シン−ナット プロダクツ エンタープライズ エルエルシー ジシクロプラチンの製造方法
WO2016172393A1 (en) 2015-04-22 2016-10-27 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
JP6851989B2 (ja) 2015-05-18 2021-03-31 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬用共結晶及びその用途
US10980768B2 (en) 2015-06-19 2021-04-20 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
KR20180018800A (ko) 2015-06-19 2018-02-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 카보플라틴 계 공-결정의 약제학적 조성물 및 이의 용도
CA2989001A1 (en) 2015-06-25 2016-12-29 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof

Also Published As

Publication number Publication date
EP3297636B1 (en) 2021-02-17
CA2988992A1 (en) 2016-12-22
EP3297636A1 (en) 2018-03-28
US10421770B2 (en) 2019-09-24
JP6768716B2 (ja) 2020-10-14
AU2016279099B2 (en) 2021-09-23
CN107847508B (zh) 2020-10-02
EP3297636A4 (en) 2018-11-14
US20180179240A1 (en) 2018-06-28
JP2018524320A (ja) 2018-08-30
KR20180018800A (ko) 2018-02-21
WO2016205785A1 (en) 2016-12-22
CN107847508A (zh) 2018-03-27
AU2016279099A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
BR112017023269A2 (pt) métodos para tratamento de câncer
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
BR112017011411A2 (pt) antagonistas da miostatina ou da activina para o tratamento da sarcopenia
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
BR112016025312A2 (pt) variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112016030730A8 (pt) composto
CY1121554T1 (el) Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης
CY1124596T1 (el) Φαρμακευτικη συνθεση τραμαδολης για οφθαλμικη χρηση
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112017003705A2 (pt) compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου
BR112017027285A2 (pt) ?cocristal, composição farmacêutica e método para o tratamento de uma doença?
BR112017019728A2 (pt) combinações e formulações de dose fixa compreendendo etc1002 e uma ou mais estatinas e método para tratar ou reduzir o risco de doença cardiovascular
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1122923T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements